FRX vs. NVO, DNA, TLRY, SLS, VBV, CUS, AIM, IPA, APM, and GXE
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), Tilray Brands (TLRY), Solaris Resources (SLS), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), and Gear Energy (GXE). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs.
Fennec Pharmaceuticals (TSE:FRX) and Novo Resources Corp. (NVO.V) (CVE:NVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.
52.8% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novo Resources Corp. (NVO.V) has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Novo Resources Corp. (NVO.V)'s return on equity.
In the previous week, Fennec Pharmaceuticals and Fennec Pharmaceuticals both had 1 articles in the media. Novo Resources Corp. (NVO.V)'s average media sentiment score of 1.00 beat Fennec Pharmaceuticals' score of 0.34 indicating that Novo Resources Corp. (NVO.V) is being referred to more favorably in the news media.
Fennec Pharmaceuticals received 75 more outperform votes than Novo Resources Corp. (NVO.V) when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 69.05% of users gave Novo Resources Corp. (NVO.V) an outperform vote.
Novo Resources Corp. (NVO.V) has lower revenue, but higher earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Novo Resources Corp. (NVO.V), indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats Novo Resources Corp. (NVO.V) on 10 of the 13 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy FRX Stock Free FRX Stock Alerts